ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
1 hedge funds and large institutions have $5.52K invested in ELITE PHARMACEUTICAL in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
45% less capital invested
Capital invested by funds: $10.1K → $5.52K (-$4.54K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBL
Sargent Bickham Lagudis
Boulder,
Colorado
|
-$4K |
ELI Hedge Fund Activity: Q4 2017 in Review
1 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2017, worth a combined $5.52K — down 45% from $10.1K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Sargent Bickham Lagudis, exiting entirely with an estimated $4K sold.
- 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q4 2017, down from 2 in Q3 2017.
- Funds reported $5.52K of ELITE PHARMACEUTICAL stock for Q4 2017, down 45% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2017 and 1 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL seller in Q4 2017 was Sargent Bickham Lagudis, an estimated $4K sold.
Based on aggregated 13F filings for Q4 2017.